In this regard, it will be important to determine whether in those advanced breast cancers that display active TGFβ signaling, higher endogenous Par6 levels correlate with better patient prognosis due to enhanced TGFβ-dependent tumor suppression and/or improved therapy response. The gene discussed is PARD6A; the disease is neoplasm.